Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

806.50 +23.32 (+2.98%)
Streaming Delayed Price Updated: 11:01 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
Via Benzinga
Eli Lilly vs. Berkshire Hathaway: Which Stock Will Become the Next Member of the $1 Trillion Club?
Don't assume that because Berkshire is worth nearly $900 billion, it's sure to get to $1 trillion first. 
Via The Motley Fool
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators. 
Via The Motley Fool
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. 
Via The Motley Fool
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
The Best Stocks to Invest $10,000 in Right Now
These elite enterprises can help you grow richer. 
Via The Motley Fool
Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Prediction: This Will Be the Next "Magnificent Seven" Stock
This particular company's growth is set to take off... 
Via The Motley Fool
US Companies In Japan Wary On Market Intervention As Yen Hits 34-Year Low Vs. Dollar
The Japanese yen fell Wednesday to a 34-year low against the dollar, which is a boon for exporters, but imports are more expensive. 
Via Benzinga
The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months
Let's review what Wall Street analysts believe are potentially the stocks to double over the next 12 months. 
Via InvestorPlace
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand. 
Via Benzinga
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its... 
Via Benzinga
Viking Surges After Weight-Loss Pill Tops Expectations In Just 28 Days
People lost more weight than the company expected over a 28-day study. 
Via Investor's Business Daily
Tuesday Talk: Big-Tech Under Attack
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. 
Via Talk Markets
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
Find out why investment banks up and down Wall Street have big expectations for these stocks. 
Via The Motley Fool
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year. 
Via Investor's Business Daily
Biotechnology And Healthcare, A Bit Of A Lull
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors. 
Via Talk Markets
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer. 
Via Benzinga
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants. 
Via The Motley Fool
Amazon’s AI Awakening: Why AMZN Stock Is the Magnificent Seven’s Sleeping Giant
While garnering relatively less attention than its "Magnificent Seven" peers, AMZN stock is a top buy among this elite set of tech stocks. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Hedge Funds Are Fleeing Tech: 7 Stocks They’re Buying Instead
Although tech remains a hot commodity, these stocks hedge funds are buying suggest that a high-level rotation is occurring. 
Via InvestorPlace
59% of This Vanguard ETF Is Invested in the "Magnificent Seven" Stocks. Is It a No-Brainer Buy Right Now?
If you want to own all of the Magnificent Seven stocks plus other megacap winners, this ETF could be right up your alley. 
Via The Motley Fool
Topics ETFs
SPDR ETF Report For Friday, March 22
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Friday, March 22. 
Via Talk Markets
Topics ETFs
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend. 
Via InvestorPlace
Don’t Sleep On Global Stocks
ESTX50 and DAX have kept up with SPX over the past three years and six months, even if NDX outpaces them nonetheless. 
Via Talk Markets
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.